Prime Medicine Inc (PRME)
7.085
+0.04
(+0.64%)
USD |
NASDAQ |
May 17, 16:00
7.085
0.00 (0.00%)
Pre-Market: 20:00
Prime Medicine SG&A Expense (Quarterly): 11.16M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.16M |
| December 31, 2023 | 13.08M |
| September 30, 2023 | 10.49M |
| June 30, 2023 | 10.66M |
| March 31, 2023 | 9.153M |
| December 31, 2022 | 9.625M |
| Date | Value |
|---|---|
| September 30, 2022 | 6.608M |
| June 30, 2022 | 7.365M |
| March 31, 2022 | 6.221M |
| December 31, 2021 | 7.187M |
| September 30, 2021 | 3.027M |
| December 31, 2019 | 1.252M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.252M
Minimum
Dec 2019
13.08M
Maximum
Dec 2023
7.986M
Average
8.259M
Median
SG&A Expense (Quarterly) Benchmarks
| Pacific Biosciences of California Inc | 43.75M |
| 10x Genomics Inc | 85.77M |
| Recursion Pharmaceuticals Inc | 31.41M |
| Verve Therapeutics Inc | 14.16M |
| Ginkgo Bioworks Holdings Inc | 70.29M |